Join the DDA or

Dabigatran etexilate and semaglutide tablets added to ‘do not export’ list

Ensure medicines meet needs of UK patients

November 18th 2020

Tagged: supply shortages

By Ailsa Colquhoun

From 7 November 2020, two medicines have been added to the list of medicines which must not be parallel exported from the UK: Dabigatran etexilate and Semaglutide tablets.

View the list of medicines that cannot be parallel exported from the UK (as of 7 November)

The government has produced guidance on export and hoarding of restricted medicines for wholesalers dealers licence holders  to ensure the continued supply of medicines to meet the needs of UK patients.

Hoarding or exporting a medicine on the list is considered a breach of regulation 43(2) of the Human Medicines Regulations 2012 and a contravention of the wholesale dealer licence and may lead to regulatory action by the MHRA, which could include immediate suspension of the wholesale dealer licence.

A monthly update on potential supply issues affecting both primary and secondary care is available on the Specialist Pharmacy Services (SPS) website (registration using an NHS email address required). Once set up and logged in, you will be able to access it online. Information is also posted for DDA members in the library of drug supply shortages.

New shortages not listed on the SPS website, can be reported using the shortage reporting tool.